Boehringer Ingelheim's Combivent and Afrovent
NDAs will be reviewed by FDA's Pulmonary-Allergy Drugs Advisory Committee on July 14-15. Data from NDA 20-291 for B-I's Combivent Inhalation Aerosol (ipratropium bromide/albuterol sulfate) will be reviewed for bronchospasm associated with chronic obstructive pulmonary disease. The committee also will be briefed on "general points to consider for inhalational drug product development," an upcoming Federal Register notice states. On July 15, the committee will review B-I's NDAs 20-393 and 20-394, respectively for Atrovent Nasal Spray .03% and .06%, for symptomatic relief of rhinorrhea associated with perennial rhinitis. The meeting will take place at FDA's Parklawn Building, conference rooms D&E, beginning at 8 a.m. both days
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth